ROSGQ (Rosetta Genomics) Net Income (Continuing Operations): $-12.53 Mil (TTM As of Jun. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rosetta Genomics Net Income (Continuing Operations)?

Rosetta Genomics ROSGQ Net Income (Continuing Operations) is $-12.53 Mil as of Jun. 2017.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Rosetta Genomics's Net Income (Continuing Operations) for the six months ended in Jun. 2017 was $-2.90 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2017 was $-12.53 Mil.

Rosetta Genomics  (OTCPK:ROSGQ) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Rosetta Genomics Net Income (Continuing Operations) Related Terms

Rosetta Genomics Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics Net Income (Continuing Operations) Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.70 -13.17 -14.53 -17.35 -16.23

Rosetta Genomics Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.69 -10.66 -6.61 -9.63 -2.90

Rosetta Genomics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2017 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-12.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $-12.53 Mil mean?
Rosetta Genomics (ROSGQ) has a Net Income (Continuing Operations) of $-12.53 Mil as of Jun. 2017. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' Net Income (Continuing Operations) too high?
Rosetta Genomics' current Net Income (Continuing Operations) is $-12.53 Mil.
How does Rosetta Genomics' Net Income (Continuing Operations) compare to TEAR and IDTA?
Rosetta Genomics' Net Income (Continuing Operations) of $-12.53 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Medical Diagnostics & Research company?
A good Net Income (Continuing Operations) depends on the Medical Diagnostics & Research industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Rosetta Genomics and its competitors. Rosetta Genomics's current Net Income (Continuing Operations) is $-12.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Net Income (Continuing Operations) of $-12.53 Mil. The current Net Income (Continuing Operations) is $-12.53 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Net Income (Continuing Operations) is $-12.53 Mil as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.